Back to results
US 2021/0061900 A1Published application
Antibodies and assays for ccl14
AssigneeAstute Medical, Inc.
InventorsRAVI A. VIJAYENDRAN, HUA WANG
Life of this patent
Estimating the term…
Abstract
The invention provides CCL14 antibodies.
Claims61
A monoclonal antibody or antigen binding fragment thereof which specifically binds human CCL14, wherein the monoclonal antibody or antigen binding fragment wherein the antibody or antigen binding fragment comprises:
- (i) a heavy chain variable region comprising
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 1,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 3,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 5,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 7,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 9,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 11,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 13,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 15,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 17, or
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 19;
- and
- (ii) a light chain variable region comprising
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 2,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 4,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 6,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 8,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 10,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 12,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 14,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 16,
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 18, or
- a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 20.
40 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 1, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 2 (2H3/2K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 1, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 2.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 3, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 4 (3H1/3K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 3, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 4.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 5, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 6 (4H1/4K3), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 5, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 6.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 7, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 8 (10H3/10K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 7, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 8.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 9, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 10 (12H2/12K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 9, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 10.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 11, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 12 (17H2/17K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 11, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 12.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 13, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 14 (18H1/18K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 13, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 14.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 15, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 16 (19H2/19K3), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 15, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 16.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 17, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 18 (25H2/25K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 17, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 18.
2 more elements
A monoclonal antibody or antigen binding fragment comprising:
- a heavy chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 19, and a light chain variable region comprising a CDR1, CDR2, and CDR3 sequence from SEQ ID NO:
- 20 (31H1/31K1), wherein the heavy chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 19, and the light chain variable region has at least 90% sequence similarity within the framework sequences to the framework sequences of SEQ ID NO:
- 20.
2 more elements
A monoclonal antibody pair selected from the group consisting of a 10H3/10K1-2H3/2K1 pair, a 10H3/10K1-31H1/31K1 pair, an 18H1/18K1-31H1/31K1 pair, and an 18H1/18K1-2H3/2K1 pair, or in each case a corresponding antigen binding fragment thereof.
A monoclonal antibody or antigen binding fragment which specifically binds human CCL14 and that binds to an epitope on human CCL14 that comprises all or part of the sequence HSVCTNPSDKWVQDYI (SEQ ID NO:
- 23).
A kit according to claim 58, wherein the monoclonal antibody or antigen binding fragment thereof is 10H3/10K1 or antigen binding fragment thereof;
- and wherein the second monoclonal antibody or antigen binding fragment thereof is 31H1/31K1 or antigen binding fragment thereof.
Dependencies are inferred from the claim text.